Dapagliflozin in Patients with Heart Failure and Reduced Ejection FractionJohn J.V. McMurray, Anna-Maria Langkilde, Subodh Verma et al.|New England Journal of Medicine|2019Cited by 6.8k
Regional Variation in Patients and Outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) TrialMarc A. Pfeffer, Bertram Pitt, Brian Claggett et al.|Circulation|2014Cited by 1k
2017 Cardiovascular and Stroke Endpoint Definitions for Clinical TrialsKaren A. Hicks, Robert J. Temple, Kenneth W. Mahaffey et al.|Circulation|2018Cited by 712
Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fractionScott D. Solomon, Marc A. Pfeffer, Brian Claggett et al.|European Heart Journal|2015Cited by 524
The Prevalence and Importance of Frailty in Heart Failure with Reduced Ejection Fraction – An Analysis of PARADIGM-HF and ATMOSPHEREPooja Dewan, John J.V. McMurray, Alice M. Jackson et al.|European Journal of Heart Failure|2020Cited by 141